Cargando…

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin

AIMS/INTRODUCTION: To identify the effect of combination therapy with a dipeptidyl peptidase‐4 inhibitor and a sodium–glucose cotransporter 2 inhibitor compared with switching from a dipeptidyl peptidase‐4 inhibitor to a sodium–glucose cotransporter 2 inhibitor on improving the glucose variability i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miya, Aika, Nakamura, Akinobu, Cho, Kyu Yong, Kawata, Shinichiro, Nomoto, Hiroshi, Nagai, So, Sugawara, Hajime, Taneda, Shinji, Tsuchida, Kazuhisa, Omori, Kazuno, Yokoyama, Hiroki, Takeuchi, Jun, Aoki, Shin, Kurihara, Yoshio, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354506/ https://www.ncbi.nlm.nih.gov/pubmed/33325645 http://dx.doi.org/10.1111/jdi.13479

Ejemplares similares

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study
por: Cho, Kyu Yong, et al.
Publicado: (2021)

Favourable effect of the sodium‐glucose co‐transporter‐2 inhibitor canagliflozin plus the dipeptidyl peptidase‐4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open‐label, prospective, randomized, parallel‐group comparison trial (the CALMER study)
por: Cho, Kyu Yong, et al.
Publicado: (2019)

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
por: Cho, Kyu Yong, et al.
Publicado: (2020)

Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study
por: Kameda, Reina, et al.
Publicado: (2020)

Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)
por: Nomoto, Hiroshi, et al.
Publicado: (2022)

Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study)
por: Nomoto, Hiroshi, et al.
Publicado: (2022)

Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
por: Cho, Kyu Yong, et al.
Publicado: (2018)

ODP190 Efficacy of Esaxerenone on Hypertensive Patients with Type 2 Diabetes or Those with Impaired Glucose Tolerance
por: Kuwabara, Saki, et al.
Publicado: (2022)

Glucokinase is required for high‐starch diet‐induced β‐cell mass expansion in mice
por: Tsuchida, Kazuhisa, et al.
Publicado: (2021)

Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function
por: Yamauchi, Yuki, et al.
Publicado: (2022)

The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
por: Kitao, Naoyuki, et al.
Publicado: (2017)

Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment
por: Nomoto, Hiroshi, et al.
Publicado: (2019)

Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial
por: Miya, Aika, et al.
Publicado: (2017)

Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study)
por: Nomoto, Hiroshi, et al.
Publicado: (2021)

Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment
por: Miya, Aika, et al.
Publicado: (2020)

Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea
por: Omori, Kazuno, et al.
Publicado: (2018)

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Takase, Takahiro, et al.
Publicado: (2018)

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
por: Chiba, Koki, et al.
Publicado: (2020)

Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis
por: Miyoshi, Arina, et al.
Publicado: (2020)

Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: a prospective observational study
por: Handa, Takahisa, et al.
Publicado: (2021)

Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring
por: Miya, Aika, et al.
Publicado: (2021)

Gitelman's syndrome with hyperphosphatemia, effectively responding to single oral magnesium oxide administration: A case report
por: Miya, Aika, et al.
Publicado: (2019)

MON-492 A Case of Gitelman’s Syndrome with Hyperphosphatemia That Responded Effectively to Single Oral Administration of Magnesium Oxide
por: Miya, Aika, et al.
Publicado: (2019)

ODP338 Neuromedin B Receptor Antagonist Suppresses ACTH Secretion and Cell Proliferation in Human and Mouse Corticotroph Adenoma
por: Atsumi, Tatsuya, et al.
Publicado: (2022)

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

ODP332 Maternal Central Diabetes Insipidus Immediately after Delivery, Owing to Vasospasm of the Internal Carotid Artery
por: Yokozeki, Kei, et al.
Publicado: (2022)

ODP285 A Case of Encephalitis and Adrenal Insufficiency in a Patient With Panhypopituitarism After COVID-19 Vaccination
por: Yabe, Ichiro, et al.
Publicado: (2022)

A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin
por: Nomoto, Hiroshi, et al.
Publicado: (2017)

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
por: Cho, Kyu Yong, et al.
Publicado: (2020)

Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

ODP328 Longitudinal Multidisciplinary Approach for Cabergoline-Resistant Aggressive Prolactinoma Complicated by Multiple Endocrine Neoplasia Type 1
por: Furusawa, Sho, et al.
Publicado: (2022)

Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Potential Importance of a Histopathological Analysis in Thyroidal Diseases with High Serum IgG4 Levels
por: Nomoto, Hiroshi, et al.
Publicado: (2017)

Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study
por: Oe, Yuki, et al.
Publicado: (2022)

Impact of Glucose Loading on Variations in CD4(+) and CD8(+) T Cells in Japanese Participants with or without Type 2 Diabetes
por: Miya, Aika, et al.
Publicado: (2018)

Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study Health Study
por: Miya, Aika, et al.
Publicado: (2020)

Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study
por: Fushimi, Yoshiro, et al.
Publicado: (2020)

ODP279 A Case of Nephrogenic Diabetes Insipidus Diagnosed at an Advanced Age in a Female Patient with an AVPR2 Gene Mutation and Skewed×Inactivation
por: Nakata, Kento, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u9ombaddboosfkba9e0cfj4aei